Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

NCT04530344 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04530344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04530344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Completed
Start date
September 24, 2020
Completion date
November 14, 2022
Enrollment
458 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

vitiligo